Your browser doesn't support javascript.
loading
Restoring the oncosuppressor activity of microRNA-34a in glioblastoma using a polyglycerol-based polyplex.
Ofek, Paula; Calderón, Marcelo; Mehrabadi, Fatemeh Sheikhi; Krivitsky, Adva; Ferber, Shiran; Tiram, Galia; Yerushalmi, Noga; Kredo-Russo, Sharon; Grossman, Rachel; Ram, Zvi; Haag, Rainer; Satchi-Fainaro, Ronit.
Afiliação
  • Ofek P; Department of Physiology and Pharmacology, Tel Aviv University, Tel Aviv, Israel.
  • Calderón M; Institute of Chemistry and Biochemistry, Freie Universität Berlin, Berlin, Germany.
  • Mehrabadi FS; Institute of Chemistry and Biochemistry, Freie Universität Berlin, Berlin, Germany.
  • Krivitsky A; Department of Physiology and Pharmacology, Tel Aviv University, Tel Aviv, Israel.
  • Ferber S; Department of Physiology and Pharmacology, Tel Aviv University, Tel Aviv, Israel.
  • Tiram G; Department of Physiology and Pharmacology, Tel Aviv University, Tel Aviv, Israel.
  • Yerushalmi N; Rosetta Genomics, Rehovot, Israel.
  • Kredo-Russo S; Rosetta Genomics, Rehovot, Israel.
  • Grossman R; Department of Neurosurgery, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • Ram Z; Department of Neurosurgery, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • Haag R; Institute of Chemistry and Biochemistry, Freie Universität Berlin, Berlin, Germany.
  • Satchi-Fainaro R; Department of Physiology and Pharmacology, Tel Aviv University, Tel Aviv, Israel. Electronic address: ronitsf@post.tau.ac.il.
Nanomedicine ; 12(7): 2201-2214, 2016 10.
Article em En | MEDLINE | ID: mdl-27262933
ABSTRACT
Glioblastoma multiforme (GBM) is the most common and aggressive primary neoplasm of the brain. Poor prognosis is mainly attributed to tumor heterogeneity, invasiveness, and drug resistance. microRNA-based therapeutics represent a promising approach due to their ability to inhibit multiple targets. In this work, we aim to restore the oncosuppressor activity of microRNA-34a (miR-34a) in GBM. We developed a cationic carrier system, dendritic polyglycerolamine (dPG-NH2), which remarkably improves miRNA stability, intracellular trafficking, and activity. dPG-NH2 carrying mature miR-34a targets C-MET, CDK6, Notch1 and BCL-2, consequently inhibiting cell cycle progression, proliferation and migration of GBM cells. Following complexation with dPG-NH2, miRNA is stable in plasma and able to cross the blood-brain barrier. We further show inhibition of tumor growth following treatment with dPG-NH2-miR-34a in a human glioblastoma mouse model. We hereby present a promising technology using dPG-NH2-miR-34a polyplex for brain-tumor treatment, with enhanced efficacy and no apparent signs of toxicity.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / MicroRNAs Limite: Animals / Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / MicroRNAs Limite: Animals / Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article